Capstone Therapeutics   Report issue

For profit Phase 2 Phase 3
Founded: Tempe AZ United States (1987)
Status: Defunct (2020)

Organization Overview

First Clinical Trial
2004
NCT00131482
First Marketed Drug
2019
bendamustine (treanda)
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Celerity Pharmaceuticals | CELERITY PHARMS | Gage Development Company, LLC

Active Ingredients

Marketed Drugs (3)

bendamustine (treanda) (2019)

doxorubicin (Doxil) (2022)

insulin human (humulin) (2019)

Drugs in Phase 3 Trials (4)

clindamycin (cleocin) (1 trial)

diclofenac (voltaren) (1 trial)

gdc 695 (1 trial)

metronidazole (flagyl) (1 trial)

Drugs in Phase 2 Trials (2)

azx100 (3 trials)

tp-508 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acne Vulgaris (Phase 3)

Cicatrix (Phase 2)

Keloid (Phase 2)

Keratosis (Phase 3)

Keratosis, Actinic (Phase 3)

Radius Fractures (Phase 2)

Vaginal Diseases (Phase 3)

Vaginosis, Bacterial (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 6